Nanjing-based Contract Research Organization (CRO) Caremo has reportedly secured RMB 150 million (USD 22.3 million) in a Series A financing round. The funding was led by Shapuaisi Pharma, with participation from Jolmo Investment, Bondshine Capital, and Huzhou Chunsheng Enterprise Management Partnership Limited. The proceeds will be utilized for constructing a research and development (R&D) headquarters and a CRO service platform, as well as for team expansion.
Company Services
Caremo offers a comprehensive range of services, including drug screening, cell biology, pharmacological efficacy, drug metabolism, non-clinical safety evaluation, formulation technology, and clinical research. This financing milestone underscores the growing investment interest in the CRO sector, with 158 financings reported this year alone.-Fineline Info & Tech
